FigureAsia 35 Under 35 · Healthcare
Deniz Kent
Age 32 · Biomanufacturing and cell-process control · California, United States
Founder whose company entered an FDA emerging-technology pathway, received a 2025 global-health grant and reported a 21 g/L antibody titre in 2026.
- Approximate age at 31 December 2025
- 32
- Field
- Healthcare
- Country or region
- California, United States
- FigureAsia U35 Assessment
- 88.1 / 100
Profile
Career and documented record
Biologic medicines are expensive partly because living cells are difficult to control at industrial scale. Deniz Kent's company uses light-responsive biology to regulate cellular behaviour during production, seeking more precise control than conventional changes to media or temperature. In 2025, the platform entered the US regulator's Emerging Technology Program and received a US$199,555 global-health grant to develop tunable production of multispecific antibodies.
In May 2026, the company reported a monoclonal-antibody titre of 21 grams per litre in a 15-day intensified fed-batch CHO process, compared with customary industry titres below ten grams per litre. The result is potentially important but remains company-reported, not a peer-reviewed, independently replicated manufacturing standard.
Kent's personal agency is direct: he is a scientific founder, trained in cell biology, and the accountable chief executive. The public-health relevance depends on what follows — reproducibility, quality attributes, process transfer and actual reduction in cost. FigureAsia recognizes a platform that could change the economics of biologics while refusing to convert a record claim into established commercial performance.
FigureAsia selection
Why Deniz Kent is on the list
FigureAsia selected Kent because he has tied an original process-control idea to a specific access problem and moved it into regulator engagement and a funded antibody programme. The 2026 titre gives the work a measurable centre. His score is moderated because the key performance claim is organization-reported and because no approved medicine or demonstrated price reduction has yet resulted.
Verified work
The 2025–26 record
Principal milestone
21 g/L monoclonal-antibody titre reported in 2026
Evidence record
15-day intensified fed-batch CHO process
Scale or implementation
US$199,555 global-health grant awarded in November 2025
Field context
The work in its field
Within biomanufacturing and cell-process control, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
88.1out of 100
Substantive 2025–2026 contribution
18 / 20
The score reflects completed 2025–26 work in biomanufacturing and cell-process control, assessed at the documented maturity of bioprocess development and regulatory engagement.
Verified impact
13.5 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
10 / 10
The work creates or materially advances a distinctive capability within biomanufacturing and cell-process control rather than relying on title or institutional association.
Field and industry influence
8 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
10 / 10
Named authorship and the documented role of Cofounder and Chief Executive Officer establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4.5 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
4.5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Founder with family roots in Antioch in southern Türkiye.
Clinical and scientific validity
4.9 / 7
Clinical and scientific validity is calibrated to bioprocess development and regulatory engagement, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
4.9 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
4.8 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
5 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.